建立人結(jié)腸癌細(xì)胞株SW480裸鼠移植瘤模型，觀察8肽生長(zhǎng)抑素(SMS 201-995，SMS)對(duì)移植瘤的作用及機(jī)理。結(jié)果∶SMS組及SMS+PG(5肽胃泌素)組移植瘤的體積、重量、瘤細(xì)胞內(nèi)cAMP、DNA、蛋白質(zhì)含量、S期和G2M期細(xì)胞數(shù)及增殖指數(shù)均顯著低于PG組及對(duì)照組，PG組顯著高于對(duì)照組；而G0/G1期細(xì)胞數(shù)則顯著高于PG組及對(duì)照組，PG組顯著低于對(duì)照組。本實(shí)驗(yàn)結(jié)果提示：生長(zhǎng)抑素具有直接抑制人結(jié)腸癌細(xì)胞株SW480移植瘤生長(zhǎng)的作用，又可抑制胃泌素對(duì)移植瘤的促增殖作用。這種作用機(jī)理是通過抑制瘤細(xì)胞內(nèi)cAMP、DNA和蛋白質(zhì)的合成，從而抑制瘤細(xì)胞從G0/G1期進(jìn)入到S期和G2M期。這為大腸癌患者應(yīng)用生長(zhǎng)抑素類似物進(jìn)行內(nèi)分泌治療提供了實(shí)驗(yàn)依據(jù)。
引用本文： 何雙梧,趙言明,沈康強(qiáng). 生長(zhǎng)抑素對(duì)人結(jié)腸癌裸鼠移植瘤的作用及機(jī)理. 中國(guó)普外基礎(chǔ)與臨床雜志, 1999, 6(1): 1-3. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Itzeu BD, Lolova I, Davidoff M.Immunocytochemical and electromicroscopical data on the differentiation of somatostatincantaining cells in human lage intestin. Anat Anz Jena, 1988; 166(2)∶77. |
| 2. | Smith JP, Solomon TE. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology, 1988; 95(6)∶1541. |
| 3. | Radulovic S, Schally AV, Reile H, et al. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC160) on HT29 human colon cancers in nude mice. Acta Oncol, 1994; 33(6)∶693. |
| 4. | Dy DY, Whitehead RH, Morris DL. SMS 201995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res, 1992; 52(2)∶917. |
| 5. | Singh P, Syle S, Townsend CM. A long acting somatostatin analog (SRIF) (201995) and proglumide (PGL) inhibit the trophic and gastrin receptor (GR) regulatory of effects of pentagastrin (PG) on mouse colon cancer (MC26) cells in vivo. Gastroenterology, 1986; 90(10)∶1636. |
| 6. | 黃廣建. 生長(zhǎng)抑素在腫瘤診治中的應(yīng)用. 國(guó)外醫(yī)學(xué)外科學(xué)分冊(cè)， 1996； 23(2)∶84. |
| 7. | Cascinu S, Ferro EO, Catalano G. A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer, 1995; 71(2)∶97. |
- 1. Itzeu BD, Lolova I, Davidoff M.Immunocytochemical and electromicroscopical data on the differentiation of somatostatincantaining cells in human lage intestin. Anat Anz Jena, 1988; 166(2)∶77.
- 2. Smith JP, Solomon TE. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology, 1988; 95(6)∶1541.
- 3. Radulovic S, Schally AV, Reile H, et al. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC160) on HT29 human colon cancers in nude mice. Acta Oncol, 1994; 33(6)∶693.
- 4. Dy DY, Whitehead RH, Morris DL. SMS 201995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res, 1992; 52(2)∶917.
- 5. Singh P, Syle S, Townsend CM. A long acting somatostatin analog (SRIF) (201995) and proglumide (PGL) inhibit the trophic and gastrin receptor (GR) regulatory of effects of pentagastrin (PG) on mouse colon cancer (MC26) cells in vivo. Gastroenterology, 1986; 90(10)∶1636.
- 6. 黃廣建. 生長(zhǎng)抑素在腫瘤診治中的應(yīng)用. 國(guó)外醫(yī)學(xué)外科學(xué)分冊(cè)， 1996； 23(2)∶84.
- 7. Cascinu S, Ferro EO, Catalano G. A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer, 1995; 71(2)∶97.